Detalhe da pesquisa
1.
Prognostic value of EndoPredict test in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative primary breast cancer screened for the randomized, double-blind, phase III UNIRAD trial.
ESMO Open
; 9(5): 103443, 2024 Apr 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-38692082